Favorable Press Coverage Somewhat Unlikely to Affect Adaptimmune Therapeutics PLC (ADAP) Share Price
News headlines about Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have trended positive on Friday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Adaptimmune Therapeutics PLC earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.5028434173029 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news articles that may have effected Accern’s scoring:
- Adaptimmune Therapeutics PLC (ADAP) Upgraded at Zacks Investment Research (americanbankingnews.com)
- Technical Analysis of Adaptimmune Therapeutics plc (ADAP), Identify Buy Sell Signals – Wall Street Morning (wallstreetmorning.com)
- Advice by Analysts to Buy stock: Adaptimmune Therapeutics plc (ADAP) – Street Observer (press release) (streetobserver.com)
- Adaptimmune Therapeutics (ADAP) Presents At LEERINK Partners Roundtable Series On Rare Disease And Immuno-Oncology – Slideshow (seekingalpha.com)
A number of analysts have recently weighed in on the company. Zacks Investment Research upgraded Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a research report on Wednesday. BidaskClub upgraded Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Sunday, July 16th. Leerink Swann reiterated an “outperform” rating and set a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 8th. Finally, ValuEngine upgraded Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Adaptimmune Therapeutics PLC currently has an average rating of “Hold” and an average price target of $12.38.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded down 4.45% during trading on Friday, hitting $8.15. The stock had a trading volume of 322,928 shares. Adaptimmune Therapeutics PLC has a 52 week low of $3.76 and a 52 week high of $9.29.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.24). The company had revenue of $3.52 million during the quarter, compared to analyst estimates of $5.43 million. Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. On average, equities research analysts anticipate that Adaptimmune Therapeutics PLC will post ($0.99) earnings per share for the current year.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.